Pharmacological Mechanism and Drug Research Prospects of Ginsenoside Rb1 as an Antidepressant
Antioxidants · 19.02.2025 · 14 (2) · 238
DOI: 10.3390/antiox14020238 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Antioxidants, online erschienen am 19.02.2025. Verfasst von Shuhui Zhuang und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemical Engineering, Changchun University of Technology, Changchun 130012, China. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jilin Province Science and Technology Department, Jilin Provincial Department of Science and Technology.
Abstract (Originalsprache)
This review explores the antidepressant effects of ginsenoside Rb1, a natural compound in traditional Chinese medicine, and its potential for treating major depressive disorder (MDD). The aetiology of depression was reviewed up to 2024, focusing on the pathways and mechanisms through which ginsenoside Rb1 may exert its effects. Notably, ginsenoside Rb1 regulates oxidative stress and inflammatory processes while enhancing neural plasticity by downregulating miR-134 expression and alleviating depressive symptoms. Unlike traditional antidepressants that act on a single target, ginsenoside Rb1 interacts with multiple pathways, reflecting its potential for broader therapeutic application. To compensate for the current deficiency in animal experiments, clinical data, and research on the side effects of ginsenoside Rb1 in the treatment of depression, we reviewed some clinical data on the use of this component in the treatment of other diseases to explore its relevance to depression. Ginsenoside Rb1 is expected to serve as a novel antidepressant or as a complementary component in combination with other antidepressant compounds. However, further clinical trials and molecular studies are necessary to confirm its efficacy and potential side effects.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Chemical Engineering, Changchun University of Technology, Changchun 130012, China.
- Pharmacology Unit, School of Pharmacy, University of Camerino, Via Madonna delle Carceri 9, 62032 Camerino, Italy.
- Department of Geriatrics and General Practice, The Third Bethune Hospital of Jilin University, Changchun 130021, China.
ORCID-Profile: Massimo Ubaldi, Roberto Ciccocioppo
Förderung
- Jilin Province Science and Technology Department
- Jilin Provincial Department of Science and Technology
Zitieren
APA
Zhuang, S., Shi, F., Cannella, N., Ubaldi, M., Ciccocioppo, R., Li, H., & Qin, D. (2025). Pharmacological Mechanism and Drug Research Prospects of Ginsenoside Rb1 as an Antidepressant. Antioxidants, 14(2), 238. https://doi.org/10.3390/antiox14020238
Vancouver
Zhuang S, Shi F, Cannella N, Ubaldi M, Ciccocioppo R, Li H, et al. Pharmacological Mechanism and Drug Research Prospects of Ginsenoside Rb1 as an Antidepressant. Antioxidants. 2025;14(2):238. doi:10.3390/antiox14020238
BibTeX
@article{Zhuang2025,
author = {Zhuang, Shuhui and Shi, Fuqiang and Cannella, Nazzareno and Ubaldi, Massimo and Ciccocioppo, Roberto and Li, Hongwu and Qin, Di},
title = {Pharmacological Mechanism and Drug Research Prospects of Ginsenoside Rb1 as an Antidepressant},
journal = {Antioxidants},
year = {2025},
volume = {14},
number = {2},
pages = {238},
doi = {10.3390/antiox14020238}
}
EUVIMED